Navigation Links
Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Date:5/14/2008

ncer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers, as well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has not been approved by any regulatory authority for use in humans. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding Poniard's (the "Company's") business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre- clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2007 and the Company's Quarterly Report for the period ended March 31, 2008. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any f
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 2014  Aethlon Medical, Inc. (OTCQB: AEMD), the ... infectious disease, cancer and other life-threatening conditions, disclosed ... (DARPA) has informed the Company that it plans ... four of a five-year $5.9 million contract that ... under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
(Date:9/22/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) will ... ended July 31, 2014 on Monday, September 29 before the ... results at 11:00 AM ET. Participating in the call will ... Krakauer , President and CEO; Jorgen B. Hansen , ... Senior Vice President, CFO and Treasurer; and Seth Yellin ...
(Date:9/22/2014)... SAN FRANCISCO , Sept. 22, 2014  Sutro ... FierceBiotech as one of 2014,s Fierce 15 ... promising private biotechnology companies in the industry.  ... A-list group of backers as well as industry partners ... developing antibody-drug conjugates and bispecifics," says John Carroll ...
Breaking Medicine Technology:Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3
... Statistically Significant and Clinically Relevant, Results ... Neuropathy, SAN FRANCISCO, June 8 Sangamo ... presentation of encouraging Phase,1b clinical data from its ... the American Diabetes Association (ADA). As,disclosed in an ...
... Control Are, Not Statistically Significant but Show Favorable Trend in Reducing Most ... ... FRANCISCO, June 8 Findings from the Veterans,Affairs Diabetes Trial (VADT), a ... today at the 68th Scientific Sessions of the American Diabetes,Association (ADA). According ...
Cached Medicine Technology:Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 9Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 2Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 3Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R) 4
(Date:9/22/2014)... Reinberg HealthDay Reporter MONDAY, ... all children aged 6 months and older be vaccinated for ... updated their influenza vaccine recommendations to advise that the youngest ... immunity. The AAP also wants parents of children aged 2 ... vaccine instead of the flu shot if it,s readily available. ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... 2014 Quincy Bioscience, one of ... promotes National Self-Improvement Month this September. ... should have access to self-improvement resources, especially for ... demand for products that preserve health is growing ... For over six years, Quincy Bioscience has been ...
(Date:9/22/2014)... 2014 (HealthDay News) -- Scans of young children,s ... read. This finding could potentially allow doctors to ... early on, preliminary research suggests. "Early identification ... dyslexia as well as most neurodevelopmental disorders," the ... professor of child and adolescent psychiatry at University ...
(Date:9/22/2014)... September 22, 2014 In a continued ... Jeep Dodge Ram is launching an awareness campaign inspired ... (#blindeggchallenge or #ffbBEC) aims to raise awareness and funds ... throwing an egg in the air and trying to ... others and if a nominee does not complete the ...
Breaking Medicine News(10 mins):Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2
... Agency Region 5 this week nears completion of a $1 ... Louis Park, Minn., A pair of open house-style meetings ... 2 to 4 p.m. and 6 to 8 p.m., at ... St. EPA,s,storefront office at 6528 W. Lake St., Ste. F., ...
... Institute July 18-20, WASHINGTON, June 17 ... health plans and health networks wrestling with,market demands ... of,credentialing services., (Logo: http://www.newscom.com/cgi-bin/prnh/20030501/URACLOGO ), ... AHIP Institute, June 18-20,in San Francisco. URAC is ...
... get to its destination can mean life or death. ... services to people in need as efficiently as possible, ... three Cornell researchers are tackling in groundbreaking ways. , ... allowing associate professor of operations research Shane Henderson, assistant ...
... reported a 44-year-old woman who presented with upper right abdominal ... lobe, histopathological diagnosis of the isodensity mass in segment V ... hepatic and gumma, respectively. , This study, performed by a ... research article to be published on March 28, 2008 in ...
... to be Available for Interviews to,Discuss his Personal ... of Risks, WASHINGTON, June 17 The ... placed the public health crisis of,sudden cardiac arrest ... conversations and physicians, offices around the country., ...
... Emageon Inc.,(Nasdaq: EMAG ), a leader ... networks and imaging facilities announced,today that Chuck Jett, ... 2nd Annual Healthcare Conference on June 24-26, 2008. ... AM ET. The presentation will be,webcast at ...
Cached Medicine News:Health News:St. Louis Park Vapor Systems Installation Nearly Complete; Meeting July 10 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 2Health News:New URAC Issue Brief Answers Questions About Delegated Credentialing, Transparency in Physician Tiering Programs 3Health News:Cornell efficiency experts seek to save precious minutes in deploying ambulances 2Health News:How to diagnose peliosis hepatis 2Health News:Tim Russert's Death Provides Important Opportunity for News Media to Increase Public Awareness of How to Prevent Sudden Cardiac Arrest 2
Stainless steel flexible ruler. graduated in 1/32 inches (.8 mm) fractions, as well as mm graduations....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Rigid Endoscopes....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Medicine Products: